ASCO: Dizal's sunvozertinib produces Phase III goods in EGFR exon 20 insertion NSCLC

Dizal Pharmaceutical (SSE: 688192) reported that sunvozertinib (Zegfrovy) cut the risk of progression or death by 35% versus platinum-doublet chemotherapy in previously untreated NSCLC patients carrying EGFR exon 20 insertion mutations — data that, if they hold up to regulatory scrutiny, would give oncologists their first oral, chemotherapy-free option in this setting.

The Phase III WU-KONG28 study is a multinational, open-label, randomized trial that enrolled 324 patients across 15 countries in Asia, Europe, North America, and South America, randomized 1:1 to sunvozertinib 300 mg once daily or investigator-choice platinum-doublet chemotherapy. At the January 16, 2026 data cutoff, median progression-free survival by blinded independent central review — the primary endpoint — was 10.3 months with sunvozertinib versus 7.5 months with chemotherapy (HR 0.65; p=0.0008). The response rate diverged more sharply: 68.1% of patients on sunvozertinib achieved a response versus 35.4% on chemotherapy, with median duration of response of 11.2 months versus 7.1 months. The safety profile was consistent with prior studies of the drug, with no new signals identified and most drug-related adverse events graded 1 or 2. The data were presented as a late-breaking oral abstract at the 2026 ASCO Annual Meeting and published simultaneously in The New England Journal of Medicine.

Competitive context

The EGFR exon20ins subgroup has long been the most therapeutically neglected corner of EGFR-mutant lung cancer. Classical sensitizing mutations — deletions in exon 19 and the L858R point mutation — were addressed by a succession of tyrosine kinase inhibitors culminating in AstraZeneca's Tagrisso (osimertinib), which now dominates the first-line setting for that population. Exon 20 insertions, which account for roughly 2–3% of all NSCLC cases, proved structurally resistant to those agents: the insertion shifts the conformation of the EGFR kinase domain in a way that reduces drug binding affinity while preserving oncogenic signaling.

Sunvozertinib was designed as an irreversible, covalent inhibitor with selectivity for the mutant kinase over wild-type EGFR — a property that matters clinically because wild-type EGFR inhibition drives the rash and diarrhea that limit tolerability of earlier-generation TKIs. Dizal has previously reported activity across a range of exon20ins variants as well as in EGFR sensitizing mutations, T790M, and HER2 exon 20 insertions, though the approved indication and the WU-KONG28 population are specific to EGFR exon20ins NSCLC.

Until recently, first-line management of this population defaulted to platinum-based chemotherapy, the same regimen used as the comparator in WU-KONG28. That changed in March 2024, when the FDA granted full approval to Janssen's Rybrevant (amivantamab) in combination with carboplatin and pemetrexed for first-line exon20ins NSCLC, based on the Phase III PAPILLON trial. Amivantamab is a bispecific antibody targeting both EGFR and MET, administered intravenously, and its approval established the first targeted regimen in this line — but it retained chemotherapy as a backbone, with the attendant hematologic toxicity and infusion burden.

WU-KONG28 is the first Phase III trial to demonstrate that a targeted monotherapy, delivered orally and without cytotoxic chemotherapy, can outperform platinum doublet in this population. Cross-trial comparisons are limited by differences in patient selection, geographic distribution, and trial design, so direct numerical comparisons between sunvozertinib and amivantamab plus chemotherapy should be made cautiously.

Sunvozertinib already holds accelerated FDA approval for previously treated exon20ins NSCLC, based on response rate data from the WU-KONG1 Part B study. That approval is contingent on confirmatory evidence; WU-KONG28 provides the randomized Phase III data that could support a label expansion to the first-line setting and, potentially, conversion to full approval. In China, Dizal has already filed a new drug application for the first-line indication, which has been accepted and granted Priority Review by the National Medical Products Administration.

---

Spot something wrong? Report an issue with this article